Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
=== Capillary electrophoresis === One significant advancement in the field is the development of integrated capillary electrophoresis (CE) systems on microchips, as demonstrated by Z. Hugh Fan and D. Jed. Harrison. They created a planar glass chip incorporating a sample injector and separation channels using micromachining techniques. This setup allowed for the rapid separation of amino acids in just a few seconds, achieving high separation efficiencies with up to 6800 theoretical plates. The use of high electric fields, possible due to the thermal mass and conductivity of glass, minimized Joule heating effects, making the system highly efficient and fast. Such innovations highlight the potential of microfluidic devices in analytical chemistry, particularly in applications requiring quick and precise analyses.
In 2021, the best preserved specimen of a dinosaur's cloacal vent exterior was described for Psittacosaurus, demonstrating lateral swellings similar to crocodylian musk glands used in social displays by both sexes and pigmented regions which could also reflect a signalling function. However, this specimen on its own does not offer enough information to determine whether this dinosaur had sexual signalling functions; it only supports the possibility. Cloacal visual signalling can occur in either males or females in living birds, making it unlikely to be useful to determine sex for extinct dinosaurs.
Biko was neither a communist nor capitalist. Described as a proponent of African socialism, he called for "a socialist solution that is an authentic expression of black communalism". This idea was derided by some of his Marxist contemporaries, but later found parallels in the ideas of the Mexican Zapatistas. Noting that there was significant inequality in the distribution of wealth in South Africa, Biko believed that a socialist society was necessary to ensure social justice. In his view, this required a move towards a mixed economy that allowed private enterprise but in which all land was owned by the state and in which state industries played a significant part in forestry, mining, and commerce. He believed that, if post-apartheid South Africa remained capitalist, some black people would join the bourgeoisie but inequality and poverty would remain. As he put it, if South Africa transitioned to proportional democracy without socialist economic reforms, then "it would not change the position of economic oppression of the blacks". In conversation with Woods, Biko insisted that the BCM would not degenerate into anti-white hatred "because it isn't a negative, hating thing. It's a positive black self-confidence thing involving no hatred of anyone". He acknowledged that a "fringe element" may retain "anti-white bitterness"; he added: "we'll do what we can to restrain that, but frankly it's not one of our top priorities or one of our major concerns.
=== Addition of adjuvants === Adjuvants are materials added to improve immunogenicity of recombinant subunit vaccines. Adjuvants increase the magnitude of adaptive response to the vaccine and guide the activation of the most effective forms of immunity for each specific pathogen (e.g. increasing generation of T cell memory). Addition of adjuvants may confer benefits including dose sparing and stabilisation of final vaccine formulation. Appropriate adjuvants are chosen based on safety, tolerance, compatibility of antigen and manufacturing considerations. Commonly used adjuvants for recombinant subunit vaccines are Alum adjuvants (e.g. aluminium hydroxide), Emulsions (e.g. MF59) and Liposomes combined with immunostimulatory molecules (e.g. AS01B).
Sources: en.wikipedia.org
6 August Weather Forecast about weather forecasting in the UK; Swedish Lennart Bengtsson of the European Centre for Medium-Range Weather Forecasts; Alistair Woodroffe and Brian Webster of the Met Office; numerical calculations began in the early 1950s with computers making 10,000 calculations a second but by the mid-1980s it was one billion; Meteosat-2 launched in June 1981; Steven Burke of the London Potato Futures Association; Capt Derek Ralph in a British Caledonian BAC One-Eleven flying to Aberdeen Airport; amateur weatherman Bill Foggitt; the weather centre and Lockheed C-5 Galaxy aircraft at RAF Mildenhall; conservationist Robin Page; narrated by Muriel Gray, directed by John Dollar, made by Uden Associates 13 August Made to Measure, essentially a re-edited, slightly updated edition of the August 1986 episodes on the F1 Ford turbocharged engine, with a few minutes of new content; in May 1987 Peter Collins watches the previous San Marino Grand Prix; Ford Cosworth V6 B187 cars: engine mapping; Dick Scammel, general head of engineering; Martin Walters, chief development engineer; the engine is dismantled, and damage is found; Geoff Goddard, chief racing engine designer; electromagnetic pulses from the engine affected the working of the engine computer circuitry; rogue signals were picked up by the engine computer, so causing erratic fuel injection; French F1 driver Patrick Tambay listens to the sound of the turbo; the turbo pressure would be limited to 2.5 in 1988, before turbos were banned for the 1989 season; the Italian Grand Prix circuit; each team is allowed two sets of qualifying tyres; the tyres on the rear axle warm up before the front axle; the Honda V6 engine could produce 1200 hp; chief designer Rory Byrne, and F1 aerodynamic forces. Narrated mostly by Martin Jarvis and partly by Eleanor Bron 20 August Twang, Bang, Kerang!, about the electric guitar; the Fat Tuesdays night club, and Les Paul; Glenn Wilson of the Institute of Psychiatry in London; Louis Jordan in the late 1940s; Charlie Christian developed the Gibson-ES150; Steve Howe of Yes; Burns London manufacturing guitars; Dave Russell; the body of the guitar was made of maple, a tonewood, and the fretboard of rosewood; the sound originates from the type of wood; Jerry Donohue of Fairport Convention; pickups made by Seymour Duncan; Chet Atkins; Andy Summers of The Police and Every Breath You Take; Francis Dunnery of It Bites, and Once Around the World. Narrated by John Hedges, produced by Patrick Uden, directed by Jeremy Llewellyn-Jones, made by Uden Associates 27 August What Goes Up..., about dismantling the AGR at Sellafield; it featured Tom Marsham CBE FRS (10 November 1923 – 12 October 1989) of UKAEA at Risley, Warrington (Birchwood Park), who was the reactor manager of Calder Hall in 1956. Narrated by Sue Jay, produced by Michael Blakstad, made by Workhouse Productions 3 September Hole in the Sky, about the depletion of the ozone layer, with Sir Bob Watson at NASA; the NERC's British Antarctic Survey had been measuring ozone levels since 1957 at the Halley Research Station, and a team led by Joe Farman noticed a hole in the layer; NASA had not noticed an ozone hole on its Nimbus 7 satellite, although the satellite had picked up all of the data, as Richard Stolarski of the Goddard Space Flight Center found; the ozone hole was caused by the polar vortex over the winter, where air movements outside of Antarctica are trapped, and there is not enough light to form new ozone; some people believed that the 1982 Mexican El Chichón volcanic eruption was to blame; in 1974 F. Sherwood Rowland and Mario Molina of the University of California, Irvine found that some chlorine compounds would destroy ozone by making chlorine monoxide, and both received the 1995 Nobel Prize in Chemistry for this discovery; the Chemical Manufacturers' Association (since 2000 the American Chemistry Council) and the National Science Foundation launched a new atmospheric survey at McMurdo Station, led by Susan Solomon of the Earth System Research Laboratories; Jerry D. Mahlman of the Geophysical Fluid Dynamics Laboratory at Princeton was attempting a computer model of the Antarctic atmosphere; Rafe Pomerance of the World Resources Institute; the greenhouse effect, described by James Hansen of the Goddard Institute for Space Studies, who claimed that the Earth's temperature would be 2 degrees higher by 2000, 3 degrees higher by 2010, and 4 to 7 degrees warmer by 2030; Richard E. Benedick. Directed by Linda Harrar, produced by Paula Apsell, made by WGBH, Uden Associates, Television Trust for the Environment and Sveriges Television. Originally a Nova documentary 24 September Dirty Money, about whether the environment can be cleaned up; the UK's first anti-pollution trade fair in March 1987, attended by William Waldegrave; Father Jim Conlon and Portglenone Abbey in N Ireland, with an anaerobic digester, which saved £1000 a month in gas cost, and the manure was sold for £25,000 a year; Mike Flux of ICI; biologist Paul Johnston of Greenpeace, in Teesside; the River Tees was the second-most polluted in the UK, with Douglas Ord of Northumbrian Water; Ken Murphy, and how Greenpeace attempted to block an effluent pipe near Immingham in March 1985; John Elkington, environmental writer; BioTechnica of Llanishen in Cardiff, reclaiming contaminated land on a former highly polluted gasworks site in Lancashire; Jutta Ditfurth; Hans-Georg Peine of BASF AG, and the Sandoz chemical spill in November 1986 in Switzerland; in 1983, ICI founded the first bioplastic company, called Marlborough Biopolymers, which made polyhydroxy butyrate; Dame Anita Roddick of The Body Shop, who worked with Friends of the Earth; Peter Baylis of the NERC Environmental Satellite Laboratory, which began in 1975, in the University of Dundee's Ewing Building, and largely provided the only UK archive of satellite environmental data. Narrated by Bob Peck, produced by Edward Poulter, directed by David Sharp, made by London Scientific Films 1 October Malltime. A US production, produced by Mike Wallington, made by George Haggerty, made by Kai Productions 8 October Anything You Can Do..., about new robotics; the five houses puzzle; Richard Gregory, professor of neuropsychology at the University of Bristol; Roger Mathias of Plessey Radar and the Multi-function Electronically Scanned Adaptive Radar (MESAR), began in 1982; Henry Thompson and speech recognition at the School of Informatics, University of Edinburgh; Robert Kowalski of the Department of Computing, Imperial College London; Margaret Boden of the University of Sussex; J. Michael Brady; Paul Caplin and robotics; Roy Bottomley of Meiko Scientific, and the transputer, developed in the UK; Plessey Laboratories at the Allen Clark Research Centre, and new chemical compounds for computer chip; logic programming and heuristics; the European Eureka Prometheus Project, an expert system. Narrated by Miriam Margolyes, produced by Michael Blakstad, directed by Catherine Robins, made by Workhouse Productions 22 October Command and Control, the chain of command of nuclear weapons; it featured the Air Force Research Laboratory. Directed by Clive Syddall, made by Twenty Twenty Vision 5 November Earthquake Country, about the San Andreas fault; Robert Wallace, chief scientist of the USGS; the 1906 earthquake caused the tectonic planes to move around seven metres; geologist Grove Karl Gilbert; an earthquake in the middle section of the fault was expected for around 1988; a 5.8 earthquake on 8 June 1934; geologist Kerry Sieh and paleoseismology; if an earthquake took place, coordination would be from the Joint Forces Training Base - Los Alamitos; earthquake engineer George W. Housner of Caltech; structural engineer Ray William Clough; earthquake engineer Luis Estava Maraboto of the Engineering Institute of the National Autonomous University of Mexico. Produced by Arabella Woods, directed by John Tchalenko, made by Red Rooster Films 12 November Nature's Technology, about the different types and the modelling of animal locomotion, and legged robots; robotic hands and bioengineer Stephen Jacobsen of the University of Utah; snake-arm robots; the 1986 Adaptive Suspension Vehicle (ASV) of Ohio State University, a hexapod robot, and Vincent Vohnout; active balance and Marc Raibert; the 1965 Walking Truck of General Electric; static stability and the Odex 1 six-legged robot; biomechanics and Robert McNeill Alexander, Professor of Zoology; WABOT-2 of Waseda University, optical music recognition and the NHK Symphony Orchestra of Japan conducted by Yuzo Toyama. Narrated by Adrienne Posta, directed by David Barlow, produced by Karl Sabbagh, made by InCA 19 November Britain Can Make It?, about making kitchen units in the UK and in Germany; the dual system of apprenticeship in Germany; Sig Prais of the National Institute of Economic and Social Research; the Britain Can Make It exhibition, where the fitted kitchen was first introduced in the UK; the Hungarian designer George Fejer was largely responsible for introducing fitted kitchens; Wolfgang Luckhaus of Poggenpohl of Germany, which also developed the fitted kitchen; in the 1960s the Germans introduced chipboard for kitchen manufacturing, which became industry-standard, with wipe-clean melamine resin facing (MFC); Hilary Steedman of the NIESR, and how the Germans built kitchens to order, whereas British companies simply built kitchens, whether ordered or not; Heal's of London introduced German kitchens to the UK in the early 1970s, in a hausfest; the German SieMatic kitchen company; Doug Gregory started The Symphony Group in 1970 after seeing chipboard, developing flatpack kitchen units, the Germans did not make flatpack kitchens, only assembled kitchens; David Love, buying director of MFI, which was helped by the flatpack revolution, but it was all largely an imitation of German products, and was a mostly standard product range; Symphony introduced computer production control in the 1980s, which the Germans had introduced in the early 1970s - this allowed much more variation of manufacturing to order, which was the main German method; employees of Symphony were largely unskilled, but German workers were largely skilled apprentices, who had passed exams in manufacturing; nearly all of German kitchens were built to order, so needed skilled workers; Walter Siekmann, production manager of Poggenpohl; German furniture manufacture was found in East Westphalia (Ostwestfalen); the Germans believed in more thorough technical training, and sold their products all over the world, but British companies had less-thorough training, and did not sell as worldwide as the Germans. Narrated by John Woodvine, directed by David Habakkuk, made by Riverside Television 26 November At the Edge, about the physical limits placed upon fighter pilots when flying high G capable modern aircraft, such as the F16 and the F18. Pilots are subjected to G-LOC in the Aerospace Medicine centrifuge in San Antonio, Texas. Narrated by Ray Brooks, written, produced and directed by Chris Haws, made by InCA
G protein dependent activation of phospholipase C (PLC) which results in the breakdown of the membrane constituent phospholipid, phosphatidylinositol (4,5)-bisphosphate (PIP2) into inositol (1,4,5)-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 is one of the most effective inducers of Ca2+ increase from cytoplasmic pools and from outside the cell via opening Ca2+ channels. DAG in turn is an inducer of protein kinase C (PKC). Activation of the regulatory small GTPase, RAS. The active RAS can in turn activate RAF, a Ser/Thr kinase. In the next step mitogen-activated protein kinases (MAP kinases) are activated. (Also known as extracellular signal-regulated kinases - ERKs or MAP/ERK kinase (MEK)). As a result of the last step, ERK1 and ERK2 are activated. The phosphorylated forms of ERKs can continue the cascade by triggering activation more interacting kinases which results in altered transcriptional activity in the nucleus. Ligand binding to FPR can also induce the activation of CD38, an ectoenzyme of the surface membrane. As a result of activation NAD+ molecules will enter the cytoplasm. NAD+ is converted into cyclic ADP ribose (cADPR), a second messenger which interacts with ryanodine receptors (RyR) on the surface of the rough endoplasmic reticulum. The overall result of the process is increased cytoplasmic Ca2+ levels via the direct pathway described above and also via indirect pathways such as opening of Ca2+ channels in the cell membrane. The sustained increase of Ca2+ is required for directed migration of the cells.
The preceding beta blockers also vary in their intrinsic sympathomimetic activity and β1-adrenergic receptor selectivity (or cardioselectivity), resulting in further differences in pharmacological profiles and suitability in different contexts between them. The brain-to-blood ratios of certain beta blockers in humans have been characterized and have been found to be 50:1 for oxprenolol, 15:1 to 33:1 for propranolol, 16:1 for alprenolol, 12:1 for metoprolol, and 0.2:1 for atenolol. The blood-to-brain ratios of various other beta blockers, for instance acebutolol, bevantolol, nadolol, pindolol, and timolol, appear to be unknown.
Sources: en.wikipedia.org
"Immigrant Women in the United States: A Demographic Portrait" Jill Esbenshade (Summer 2007). "Division and Dislocation: Regulating Immigration through Local Housing Ordinances". American Immigration Council Jeffrey S. Passel & Roberto Suro (September 2005). "Rise, Peak and Decline: Trends in U.S. Immigration" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2005). "Estimates of the Size and Characteristics of the Undocumented Population" Archived 31 December 2007 at the Wayback Machine. Pew Hispanic Center Jeffrey S. Passel (March 2007). "Growing Share of Immigrants Choosing Naturalization" Archived 28 December 2007 at the Wayback Machine. Pew Hispanic Center This article incorporates public domain material from Report for Congress: Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition (PDF). Congressional Research Service. UNCTAD's Classification of Non-Tariff Measures (2012) report
Every dollar earned is just as valuable to happiness up to a $75,000 annual income, thereafter, the value of each additional dollar earns a diminishing amount of happiness. According to the latest systematic review of the economic literature on life satisfaction, one's perception of their financial circumstances fully mediates the effects of objective circumstances on one's well-being. People overestimate the influence of wealth by 100%. Professor of Economics Richard Easterlin noted that job satisfaction does not depend on salary. In other words, having extra money for luxuries does not increase happiness as much as enjoying one's job or social network. Gilbert is thus adamant, people should go to great lengths to figure out which jobs they would enjoy, and to find a way to do one of those jobs for a living (that is, provided one is also attentive to social ties). Unemployment is detrimental to individual well-being. However, that does not hold true in countries where unemployment is widespread. Psychology Today reports that the impact of unemployment is dampened in those for whom work is less central to their identity, those who receive less criticism and less negative judgments from others, those who can meet their immediate financial obligations and those who do not see their unemployment as high stress and negative. Other protective factors include the expectation of reemployment, routines that structure one's time and evaluating oneself as worthy, competent and successful.
Viola canina – heath dog violet Viola hirta – hairy violet Viola labradorica – alpine violet Viola odorata – sweet violet Viola persicifolia – fen violet Viola riviniana – common dog violet Viola rostrata – long-spurred violet Viola sororia – common blue violet, hooded violet Section Xylinosium
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.